This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

ViewRay Beheer

Beheer criteriumcontroles 1/4

De CEO ViewRay is Paul Ziegler, benoemd in Jul2023, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.039% van de aandelen van het bedrijf, ter waarde € 6.81. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.7 jaar en 3.5 jaar.

Belangrijke informatie

Paul Ziegler

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.04%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	3.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Paul Ziegler's beloning veranderd ten opzichte van ViewRay's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2023	n/a	n/a	-US$110m
Dec 31 2022	n/a	n/a	-US$107m
Sep 30 2022	n/a	n/a	-US$107m
Jun 30 2022	n/a	n/a	-US$106m
Mar 31 2022	n/a	n/a	-US$109m
Dec 31 2021	US$2m	US$350k	-US$110m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Paul redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de German markt.

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Paul te vergelijken met de prestaties van het bedrijf.

CEO

Paul Ziegler (50 yo)

less than a year

Tenure

US$2,028,555

Compensatie

Mr. Paul Ziegler. Jr., J.D., serves as President, Chief Executive Officer and Director at ViewRay, Inc. since July 2023 and was its Chief Commercial Officer since 2021 until July 2023 and served as its Exe...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Ziegler	President	less than a year	US$2.03m	0.039% € 6.8
James Dempsey	Founder & Chief Scientific Officer	19.6yrs	US$1.17m	0.16% € 28.3
Jacob Signoriello	Interim Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Drew Hill	Senior Vice President of Operations & Development	1.8yrs	geen gegevens	geen gegevens
Matt Harrison	Director of Investor Relations	no data	geen gegevens	geen gegevens
Sanket Shah	Senior VP & General Counsel	less than a year	geen gegevens	0.21% € 36.6
Karen Hackstaff	Vice President of Marketing	no data	geen gegevens	geen gegevens
Julianne Mast	Vice President of Human Resources	less than a year	geen gegevens	geen gegevens
Martin Fuss	Chief Medical Officer	no data	geen gegevens	geen gegevens
Adam Podbelski	Senior Vice President of Commercial Operations	1.8yrs	geen gegevens	0.24% € 42.3
Steven Annen	Senior Vice President of Global Marketing	less than a year	geen gegevens	geen gegevens
Ashley Kluth	Senior Manager of Investor Relations	no data	geen gegevens	geen gegevens

0.7yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 6L9 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.7 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Ziegler	President	less than a year	US$2.03m	0.039% € 6.8
Caley Castelein	Independent Director	15.8yrs	US$212.17k	0.027% € 4.7
B. Johnson	Independent Director	3.5yrs	US$208.00k	0.092% € 15.9
Brian Roberts	Independent Director	7.8yrs	US$221.00k	0.065% € 11.4
Daniel Moore	Independent Chairman	5.7yrs	US$261.00k	0.11% € 19.0
Scott Drake	Director	5.3yrs	US$5.80m	0.32% € 56.1
Karen Prange	Independent Director	2.3yrs	US$201.00k	0% € 0
Stefanie Corradini	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Enis Ozyar	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
James Good	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Lauren Henke	Member of Medical Advisory Board	less than a year	geen gegevens	geen gegevens
Rupesh Kotecha	Member of Medical Advisory Board	less than a year	geen gegevens	geen gegevens

3.5yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 6L9 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

This company is no longer active

ViewRay Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board

Viewray, Inc. Announces Resignation of Susan Schnabel from Board of Directors

ViewRay, Inc. Appoints Sai Nanduri as an Observer of the Board of Directors

ViewRay, Inc. Announces CFO Changes

Insider recently bought €113k worth of stock

President recently bought €379k worth of stock

Recent updates

Motion For Case Conversion Approved for ViewRay, Inc.

Nasdaq To Delist the Common Stock of ViewRay

ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite Index

ViewRay Announces Commencement of Nasdaq Delisting Proceedings

ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board

Motion for Joint Administration Filed by ViewRay, Inc.

Viewray, Inc. Announces Resignation of Susan Schnabel from Board of Directors

ViewRay Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.14 loss in 1Q 2022)

ViewRay, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings released: US$0.59 loss per share (vs US$0.67 loss in FY 2021)

ViewRay, Inc. to Report Q4, 2022 Results on Feb 27, 2023

ViewRay, Inc. Appoints Sai Nanduri as an Observer of the Board of Directors

ViewRay, Inc. Announces Findings from the Phase III Randomized Controlled Mirage Trial

ViewRay, Inc. Announces CFO Changes

Insider recently bought €113k worth of stock

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.15 loss in 3Q 2021)

ViewRay, Inc. Provides Revenue Guidance for the Full Year 2022

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc. Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients

ViewRay, Inc. Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy

ViewRay, Inc. to Report Q3, 2022 Results on Nov 01, 2022

ViewRay Announces China NMPA Approval of its MRIdian(R) MRI-Guided Radiation Therapy for Cancer Patients

ViewRay, Inc. Selects Denver for Headquarters

Second quarter 2022 earnings released: US$0.15 loss per share (vs US$0.19 loss in 2Q 2021)

Viewray, Inc. Updates Earnings Guidance for the Year 2022

ViewRay, Inc. to Report Q2, 2022 Results on Aug 02, 2022

President recently bought €379k worth of stock

First quarter 2022 earnings released: US$0.14 loss per share (vs US$0.17 loss in 1Q 2021)

ViewRay, Inc. Reiterates Earnings Guidance for the Year 2022

ViewRay, Inc., Annual General Meeting, Jun 10, 2022

ViewRay, Inc. to Report Q1, 2022 Results on May 05, 2022

Insider recently bought €88k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Viewray, Inc. Provides Revenue Guidance for the Year 2022

ViewRay Announces Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

ViewRay, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Chief Financial Officer recently bought €88k worth of stock

Chief Financial Officer recently bought €181k worth of stock

Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 2Q 2020)

ViewRay, Inc.(NasdaqGM:VRAY) dropped from Russell Microcap Value Index

ViewRay, Inc. Not to Provide Financial Guidance

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.19 loss in 1Q 2020)

Chief Operating Officer has left the company

ViewRay, Inc. Announces the Resignation of Shahriar Matin as Chief Operating Officer, Effective from March 31, 2021

Full year 2020 earnings released: US$0.73 loss per share (vs US$1.18 loss in FY 2019)

Revenue beats expectations

ViewRay, Inc. to Report Q4, 2020 Results on Mar 04, 2021

Independent Director has left the company

ViewRay, Inc. Announces Retirement of D. Keith Grossman from Board of Directors

Viewray, Inc. Appoints Phil Spencer to Its Board of Directors

Edogawa Hospital in Tokyo Installs Japan's First ViewRay MRIdian Linac

The Henry Ford Cancer Institute Installs Its Second Viewray Mridian® Linac

An unknown buyer acquired 7.3% stake in ViewRay, Inc. (NasdaqGM:VRAY) from Elekta AB (publ) (OM:EKTA B) for $53.5 million.

ViewRay, Inc. has completed a Follow-on Equity Offering in the amount of $50.0035 million.

New 90-day high: €4.22

New 90-day high: €3.68

New 90-day high: €3.26

President recently bought €423k worth of stock

Universitair Ziekenhuis Brussels Purchases ViewRay's MRIdian Linac

Third quarter 2020 earnings released: US$0.19 loss per share

Revenue beats expectations

ViewRay, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day high - €3.00

ViewRay, Inc. to Report Q2, 2020 Results on Jul 30, 2020

Analyse CEO-vergoeding

CEO